|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: HOLD @ $0.49
Signal Strength: MEDIUM
Cogstate (ASX:CGS) currently has positive momentum of 0.04. This means the current price is greater than the price 14 days ago and therefore gaining momentum.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Momentum measures the rate of change in closing prices and is used to detect trend weakness and likely reversal points. It is often underrated because of its simplicity. High Momentum readings (positive or negative) occur when a trend is at its strongest. Lower readings are found at the start and end of trends. Overbought and oversold levels are set separately for each security based on the performance of the indicator over past cycles.
Calculation: Momentum Oscillator (MOM):
1) Closing Price [today] - Closing Price [n days ago];
PROFILE: Cogstate (CGS.AX)
Stock Exchange: ASX
Ticker Codes: | CGS.AX | ASX:CGS |
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain injury applications primarily in Australia, the United States, and Europe. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of disease and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations. As of June 30, 2017, it had participated in approximately 1,200 academic research studies in approximately 70 indications. The Healthcare segment provides Cognigram, a system that enables regular and standardized assessment of patients to detect cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is headquartered in Melbourne, Australia.
|EWC Energy World Corporation||0.08||7.9||866,274||0.01||BULLISH|
|MAQ Macquarie Telecom||28.5||6.1||4,846||2.5||BULLISH|
|FDV Frontier Digital Ventures||1.14||3.6||44,326||0.18||BULLISH|
|PNI Pinnacle Investment Management||6.19||3.2||1,394,190||1.55||BULLISH|
|ABP Abacus Property||4.05||3.1||2,265,633||0.27||BULLISH|
|CGC Consolidated Gaming Corporation||3.1||2.6||1,524,286||0.33||BULLISH|
|FRI Finbar International||0.98||2.6||320,109||0.11||BULLISH|